Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moexipril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 15/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moexipril SCHEMBL6508276 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL29376544 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL683321 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL22175779 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL678818 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL5159178 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL40877 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL14660386 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL30903896 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL5386742 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16388 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260083968-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND ACE INHIBITORS | NOVOCURE GMBH (CH) | 2026-03-26 | — | — | US | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| EP-4684832-A2 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA | Vifor (International) Ltd. (CH) | 2026-01-28 | — | — | EP | claimed |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-12527767-B2 | Eye drops to treat chemically induced corneal damage | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2026-01-20 | — | — | US | claimed |
| EP-2916851-B1 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA | VIFOR INT LTD (CH) | 2025-12-17 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-5651985-A | DRUG IN TABLET FORM WITH POLYVINYLPYRROLIDONE AND METHACRYLIC ACID POLYMER | BAYER AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | claimed |
| WO-1997002032-A1 | METHOD OF TREATING RENAL DISEASE USING AN ACE INHIBITOR AND AN AII ANTAGONIST | MERCK & CO., INC. (US) | 1997-01-23 | — | — | WO | claimed |
| WO-1996024372-A2 | COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR, SIDE-EFFECT-REDUCED AMOUNT OF ALDOSTERONE ANTAGONIST AND DIURETIC | G.D. SEARLE & CO. (US) | 1996-08-15 | — | — | WO | claimed |
| WO-1996024373-A2 | COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND SIDE-EFFECT-REDUCED AMOUNT OF ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-08-15 | — | — | WO | claimed |
| EP-0488059-B1 | Use of a combination of an ace inhibitor with a calcium antagonist in the treatment of proteinuria | HOECHST AG (DE) | 1995-09-06 | — | — | EP | claimed |
| EP-0669129-A2 | Expandable release controlled medicaments | BAYER AG (DE) | 1995-08-30 | — | — | EP | claimed |
| WO-1994028924-A1 | COMBINATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND AII ANTAGONISTS | LABORATOIRES MERCK SHARP ET DOHME CHIBRET (FR) | 1994-12-22 | — | — | WO | claimed |
| EP-0629408-A1 | Combination of angiotensin converting enzyme inhibitors and AII antagonists | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET (FR) | 1994-12-21 | — | — | EP | claimed |
| CN-1072601-A | Angiotensin-convertion enzyme inhibitor and calcium antagonist are united and are used for the treatment of albuminuria | HOECHST AG (DE) | 1993-06-02 | — | — | CN | claimed |
| EP-0488059-A2 | Use of a combination of an ace inhibitor with a calcium antagonist in the treatment of proteinuria | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-06-03 | — | — | EP | claimed |